$223.22-3.5%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 6, 2026
Moderna sells COVID-19 vaccines mainly to wholesalers, distributors and governments, plus vaccines for respiratory syncytial virus (RSV) and influenza.
Just reported
From Moderna, Inc.'s results release of November 6, 2026; its quarterly report has since been filed.
Actual
$1.31B
+29% y/y
Guided
—
No guide given
Actual
$0.38
Guided
—
No guide given
Actual
$130M
Guided
—
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $1.3B | $1B | +29.23% |
| Profit | $162M | -$200M | +181.00% |
| Profit per share | $0.38 | -$0.51 | +174.51% |
| Free Cash Flow | -$1.6B | -$880M | -82.50% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Moderna, Inc. reported on November 6, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of its technology platform, Moderna is reimagining how medicines are made to transform how we treat and prevent diseases. Since its founding, Moderna's mRNA platform has enabled the development of vaccines and therapeutics across infectious diseases, cancer, rare diseases and more. With a global team and a unique culture, driven by the Company's values and mindsets, Moderna's mission is to deliver the greatest possible impact to people through mRNA medicines.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Moderna, Inc.’s Item 2.02 8-K filed November 6, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.